While weekly options like Semaglutide and Tirzepatide are more common in 2026, a daily option like Liraglutide might be chosen due to insurance coverage, specific patient history, or formulary preferences
The results demonstrate the analytical approach generates predictive and biologically meaningful insights from small sample sizes
Recent advancements in the pharmacological treatment of MASLD and MASH have shown promising results, particularly with medications such as Resmetirom and Fibroblast Growth Factor 21 (FGF21) analogs
For people with severe obesity, the ones the drug was actually built for, thats going to be a very big deal if the safety and durability data hold up: surgery-level weight loss from a weekly shot, under real medical supervision
This coincides with the rapid rise in GLP-1 drugs like Wegovy, Ozempic, and Mounjaro
Reduces inflammation and cholesterol GLP-1 medications decrease inflammationa key driver of heart disease